A01 Specific targeting of adipose tissue-associated metastasis using bile salt nanoparticles. Ayesha Alvero, Yale University, New Haven, CT, USA.

A02 CBX7 binds TWIST-1’s E-box to inhibit TWIST-1 function and curtail tumorigenecity and metastatic potential in ovarian cancer. Ayesha Alvero, Yale University, New Haven, CT, USA.

A03 PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high grade serous tubo-ovarian cancer. Michael Anglesio, University of British Columbia, Vancouver, BC, Canada.

A04 Real-world usage of NGS testing in high-grade serous ovarian cancer (HGSOC): The landscape is quickly changing. Rebecca Arend, University of Alabama at Birmingham, Birmingham, AL, USA.

A05 Maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC): What are we actually choosing? Hannah Beer, University of Alabama at Birmingham, Birmingham, AL, USA.

A06 Synthetic peptides derived from the cell adhesion molecule Nectin-4 inhibit the formation of ovarian cancer 3D spheroids. Kristin Boylan, University of Minnesota, Minneapolis, MN, USA.

A07 A phase II study of metformin therapy in ovarian cancer with translational endpoints. Ronald Buckanovich, University of Pittsburgh, Pittsburgh, PA, USA.

A08 A new driver pathway in ovarian cancer stem cells. Ugo Cavallaro, European Institute of Oncology, Milano, Italy.

A09 SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong inhibition of the Wnt signaling pathway and antitumor effects in diverse ovarian cancer models. Heekyung Chung, Samumed, LLC, San Diego, CA, USA.

A10 Phenotypic and genomic characterization of intra-tumoral heterogeneity in high-grade serous ovarian cancer. Paula Cunnea, Imperial College, London, UK.

A11 Copy-number analysis of understudied black women ovarian cancers. Joe Delaney, Medical University of South Carolina, Charleston, SC, USA.

A12 Analysis of advanced quantitative computed tomography imaging features in predicting the surgical resectability of advanced epithelial ovarian cancer. Paul DiSilvestro, Women And Infants Hospital, Providence, RI, USA.
A13 Therapeutic AXL inhibition with AVB-S6-500 improves response to chemotherapy and induces a homologous recombination deficiency in ovarian cancer. Katherine Fuh, Washington University School of Medicine, St. Louis, MO, USA.

A14 The chemopreventive effects of natural compounds in Romina strawberries in human ovarian cancer cells. Raisa Haq, City College of New York, CUNY School of Medicine, New York, NY, USA.

A15 Non-canonical NF-kappaB signaling is associated with poor ovarian cancer prognosis. Demetra Hufnagel, Vanderbilt University School of Medicine, Nashville, TN, USA.

A16 A novel death receptor ligand fabclavine inhibits cancer and cancer stem cell proliferation by extrinsic apoptosis. Arvinder Kapur, University of Wisconsin, Madison, WI, USA.

A17 Characterization of primary-metastasis pairs in high-grade serous ovarian cancer with short- and long-term survival. Emilee Kotnik, Washington University in St. Louis, Saint Louis, MO, USA.

A18 Evaluating the potential to repurpose statins for ovarian cancer therapy. Paul Kroeger, University of Pennsylvania, Philadelphia, PA, USA.

A19, PR03 Single cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor. Marilyne Labrie, OHSU, Portland, OR, USA.

A20 Characterizing chromosome instability in chemonaive, chemosensitive, and chemoresistant high-grade serous ovarian cancer. Claire Morden, University of Manitoba, and Research Institute in Oncology and Hematology, Winnipeg, MB, Canada.

A21 Digital vivarium cloud platform facilitates nonclinical endpoint assessment in an ovarian carcinoma xenograft model with ascites. Chibueze Nwagwu, OncoSynergy, Inc., Greenwich, CT, USA.

A22 Synchronous ovarian and uterine cancers in US women, 2004-2015. Mary Puckett, Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Atlanta, GA, USA.

A23 Ultra-rapid total abdominal FLASH irradiation in a preclinical model of ovarian cancer. Erinn Rankin, Stanford University, Stanford, CA, USA.

A24 Cell adhesion molecule (CAM)-related downregulated by oncogenes (CDON) promotes ovarian cancer adhesion and survival. Valerie Sodi, Fox Chase Cancer Center, Philadelphia, PA, USA.
A25 Withaferin A ameliorates ovarian cancer-induced cachexia through regulation of NF-kB/NLRP3 signaling. Alex Straughn, James Graham Brown Cancer Center, Louisville, KY, USA.

A26 Molecular analysis of short- vs. long-term ovarian cancer survivors. Elaine Stur, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

A27 Microsatellite instability and tumor mutation burden as factors in ovarian clear cell carcinoma therapy selection. Shiro Takamatsu, Kyoto University Graduate School of Medicine, Kyoto, Japan.

A28 Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtypes and change in treatment course. Hisamitsu Takaya, Kindai University, Osaka-sayama, Japan.

A29 Anti-cancer effects of polo-like kinase-4 inhibitor (CFI-400945) in ovarian cancer. Ka Yu Tse, The University of Hong Kong, Hong Kong, Hong Kong.

A30 Claudin-4-dependent mechanisms of high-grade serous ovarian cancer progression. Patricia Webb, The University of Colorado, Aurora, CO, USA.

A31 The two most potent PARP inhibitors increase expression levels of innate immune response genes in BRCA wild-type HGSC tumors. Monica Wielgos-Bonvallet, NYU Langone Medical Center, New York, NY, USA.

A32 Combination panobinostat and olaparib treatment promotes DNA damage and anti-tumor immunity in ovarian cancer. Andrew Wilson, Vanderbilt University Medical Center, Nashville, TN, USA.

A33 Loss of ZC3H18 disrupts homologous recombination repair and sensitizes ovarian cancer cells to PARP inhibitors and DNA cross-linking agents. Arun Kanakkanthara, Mayo Clinic, Rochester, MN, USA.

A34 Targeting protein phosphatase 2A in combination with PARP inhibitors for the treatment of high-grade serous epithelial ovarian cancer. Rita A. Avelar, University of Michigan, Ann Arbor, MI, USA.

A35 Targeting the IDH1-mediated metabolic-epigenetic axis in cyclin E-high ovarian cancer. Katherine Aird, Penn State College of Medicine, Hershey, PA, USA.

A36 Developing a novel treatment for advanced ovarian cancer by targeting the c-Met pathway. Anusha Chaparala, Northwestern University, Chicago, IL, USA.
1. **A37 PAX8 drives ovarian cancer angiogenesis through interaction with SOX17.** Daniele Chaves-Moreira, University of Pennsylvania, Philadelphia, PA, USA.

2. **A38 ATM inhibitor synergizes with glycolysis inhibition in ovarian cancer cells.** Chi-Wei Chen, Penn State College of Medicine, Hershey, PA, USA.

3. **A39 Understanding poly-ADP-ribose polymerase (PARP) inhibitor resistance in BRCA2-deficient cells through dual CRISPR knockout and activation screens.** Kristen Clements, Pennsylvania State University College of Medicine, Hershey, PA, USA.

4. **A40 Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer.** Erdogan Pekcan Erkan, University of Helsinki, Helsinki, Finland.

5. **A41 ROR1 is associated with ovarian cancer progression and chemoresistance.** Caroline Ford, UNSW Sydney, Sydney, NSW, Australia.

6. **A42 Potassium channel activity unveils ovarian cancer vulnerability: From signaling to precision medicine.** Saverio Gentile, University of Illinois Chicago, Chicago, IL, USA.

7. **A43 Centrosome amplification favours survival and impairs ovarian cancer progression.** Oumou Goundiam, Institut Curie, Paris, France.

8. **A44 A CRISPRi screen to identify combination therapies for improved treatment of ovarian cancer.** Erika Handly, MIT, Cambridge, MA, USA.

9. **A45 Quinacrine induces necrosis of ovarian high-grade serous carcinoma cells by breaking the mitochondria ROS balance.** Ching-I Huang, Tzu Chi University, Hualien, Republic of China.

10. **A46, PR01 Assessment of PARPi and cisplatin resistance in BRCA1 exon 11 mutant patient-derived xenografts.** John Krais, Fox Chase Cancer Center, Philadelphia, PA, USA.

11. **A47 Preclinical efficacy of CPI-1688, a novel EZH2 inhibitor, in epithelial ovarian cancer with alterations in the SWI/SNF chromatin remodeling complex.** Elizabeth Magno, The Wistar Institute, Philadelphia, PA, USA.

12. **A48 Anti-apoptotic gene expression and sensitivity to BH3-mimetics in chemo-resistant, high-grade serous ovarian cancer cell lines.** Cristina Mapagu, Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.
A49 Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Noriomi Matsumura, Kindai University, Osakasayama, Osaka, Japan.

A50 Lapatinib potentiates the anti-tumor effects of paclitaxel treatment in resistant ovarian cancer cells. Rob McCorkle, University of Kentucky, Lexington, KY, USA.

A51 The role of ATF6-mediate AP-1 signaling in promoting PARP inhibitor resistant ovarian cancer. Alexandra McMellen, University of Colorado Denver, Aurora, CO, USA.

A52 Serially passaging ovarian cancer spheroids as an in situ model for emergence of chemoresistance and enrichment of cancer stem cells. Geeta Mehta, University of Michigan, Ann Arbor, MI, USA.

A53 Energetic regulation of the Cyclin E onco-protein in mitochondria-dependent ovarian tumor initiating cells. Kasturi Mitra, University of Alabama, Birmingham, AL, USA.

A54 Targeting new links in the proteostasis network as novel therapies in high-grade serous ovarian cancer. Sumegha Mitra, Indiana University School of Medicine, Indianapolis, IN, USA.

A55 DCLK1 mediates tumor stemness and platinum resistance in high-grade serous epithelial ovarian cancer. Katherine Moxley, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.

A56 Novel L-sugar linked glycosylated antitumor ether lipids for killing platinum-resistant human epithelial ovarian cancer cells. Mark Nachtigal, University of Manitoba, Winnipeg, MB, Canada.

A57 Identification of novel targets for ovarian cancer treatment. Ricardo Noriega, University of Puerto Rico Medical Sciences Campus, San Juan, PR, USA.

A58 HR-ESI-MS identification of novel triterpenoid antitumor substances in securidaca 1, using activity-guided SRB assay. Titus Obasi, Iuliu Hatieganu University of Medicine and Pharmacy (UMF), Cluj-Napoca, Cluj, Romania.

A59 RNA-seq analysis of high-grade serous ovarian cancer patients before and after chemotherapy reveals chemoresistance-associated genes and pathways. Jaana Oikkonen, University of Helsinki, Helsinki, Finland.

A60 Phylogenetic analyses reveal variable patterns of tumor evolution in HGSOC. Jaana Oikkonen, University of Helsinki, Helsinki, Finland.
A61 FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. Duygu Ozmadenci, University of California San Diego Moores Cancer Center, La Jolla, CA, USA.

A62, PR02 Proteogenomic approach to identify mechanisms of platinum refractoriness in high grade serous ovarian cancers. Amanda Paulovich, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

A63 Whole-genome CRISPR/CAS9 screen using patient samples reveals JunB as a unique genetic liability. David Pepin, Massachusetts General Hospital, Boston, MA, USA.

A64 Extracellular matrix proteins increase invasive growth and chemotherapy resistance of ovarian cancer cells. Elina Pietilä, University of Helsinki, Helsinki, Finland.

A65 Spatial characterization of drug resistance in ovarian cancer. Kathleen Pishas, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

A66 Repeatome profiling in high-grade serous ovarian cancer reveals abundant repeat non-coding RNA expression. Rebecca Porter, Massachusetts General Hospital Cancer Center, Boston, MA, USA.

A67 Understanding HIF1A-mediated therapy in clear-cell ovarian cancer. Colles Price, Dana Farber Cancer Institute, Broad Institute of MIT and Harvard, Boston, MA, USA.

A68 Increasing intracellular glucose levels decreased expression of Enolase-I promoting cisplatin resistance in ovarian cancer cells. Robert Rabelo-Fernandez, University of Puerto Rico at Rio Piedras, San Juan, PR, USA.

A69 Role of mitochondrial-STAT3 in promoting chemoresistance by modulating the energy metabolism in ovarian cancer. Ramandeep Rattan, Henry Ford Hospital, Detroit, MI, USA.

A70 Studying the signaling pathways of tumorigenic epithelial fallopian tube subpopulations during early tumorigenesis. Angela Russo, University of Illinois at Chicago, Chicago, IL, USA.

A71, PR13 Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer. Elaine Sanij, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

A72 Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer. Payal Shah, University of Pennsylvania, Philadelphia, PA, USA.
Poster Session A
Saturday, Sept. 14, 2019
5-7:30 p.m.

A73 BCL-XL dependency in a subset of ovarian clear-cell carcinoma cell lines. Elizabeth Stover, Dana-Farber Cancer Institute, Boston, MA, USA.

A74 The HIV protease inhibitor nelfinavir, alone or in combination with the proteasome inhibitor bortezomib, is cytotoxic to high-grade serous ovarian cancer cells regardless of platinum sensitivity. Carlos Telleria, McGill University, Montreal, QC, Canada.


A76 Role of frizzled-7 in platinum tolerance ovarian cancer. Yinu Wang, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

A77 Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high grade serous ovarian carcinoma. Zachary Watson, University of Colorado, Aurora, CO, USA.

A78 Preexisting, poly-resistant cancer stem cells in high-grade serous ovarian cancer. Wa Xian, University of Texas, Houston, TX, USA.

A79 A novel small molecule LLL12B inhibits STAT3 Phosphorylation and sensitizes ovarian cancer cell to cisplatin and paclitaxel treatment. Ruijie Zhang, University of Maryland School of Medicine, Baltimore, MD, USA.

A80 Targeting ovarian cancer stem cell by Dot1L inhibition. Yaqi Zhang, Northwestern University, Chicago, IL, USA.

A81 Targeting EZH2/DAB2IP/Wnt axis in ovarian cancer stem cells. Xingyue Zong, Indiana University School of Medicine, Bloomington, IN, USA.